Our MOA with CP does not dismiss formation of these adducts but instead highlights that there is a threshold below which macromolecular binding is small and the cancer dose response is driven by production of reactive metabolites together with increasing levels of GSH depletion. The gene discussed is CP; the disease is cancer.